louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00002358: A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV
Official title: Open-Label BV-araU Treatment of Pediatric HIV-Infected Patients With Cutaneous, Visceral, or Ocular Varicella-Zoster Viral Disease Who Have Failed or Are Intolerant of Standard Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: HIV Infections
Chickenpox
Keywords: Herpes Zoster
Acquired Immunodeficiency Syndrome
AIDS-Related Complex
Antiviral Agents
sorivudine
Chickenpox
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2001-08-31
Sex: ALL
Minimum age (years): 2
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: To provide oral sorivudine ( BV-araU ) to pediatric HIV-infected patients with varicella-zoster viral disease who have failed or are intolerant of alternative therapy.

Detailed description: Any physician qualified to treat pediatric AIDS patients may enroll patients in this study.

Eligibility criteria: Inclusion Criteria

Patients must have:

* HIV infection.
* Cutaneous, visceral, or ocular varicella-zoster viral infection.
* Refractory or intolerant to acyclovir or foscarnet therapy.
* Consent of parent or guardian.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

* Inability to take oral capsules or tolerate liquids.

Concurrent Medication:

Excluded:

* 5-flucytosine, 5-fluorouracil, high-dose prednisone, or probenecid.

Patients with the following prior condition are excluded:

History of immediate hypersensitivity to nucleoside analogues.

Prior Medication:

Excluded:

* 5-flucytosine, 5-fluorouracil, high-dose prednisone, or probenecid within 4 weeks prior to study entry.

Required:

* Prior acyclovir or foscarnet.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Wallingford
country: United States
facility: Bristol - Myers Squibb Co
state: Connecticut
Study officials:
References:
Clinical trial NCT03036358: Effect of Teledermatology on Length of Hospital Admission, Length of Stay, 30 Day Readmission Rate, and Antibiotic Use in Patients Presenting With Cellulitis vs Pseudocellulitis in an Academic ED Setting
Official title: The Effect of Teledermatology on Length of Hospital Admission, Length of Stay, 30 Day Readmission Rate, and Antibiotic Use in Patients Presenting With Cellulitis vs Pseudocellulitis in an Academic Emergency Department Setting.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cellulitis
Lead sponsor: Ohio State University
Sponsor class: OTHER
First posted: 2017-01-30
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The effect of teledermatology on length of hospital admission, length of stay, 30 day readmission rate, and antibiotic use in patients presenting with cellulitis vs pseudocellulitis in an academic emergency department setting.

Detailed description: The Investigator hope to determine if the implementation of teledermatology in the emergency department (ED) at The Ohio State University Wexner Medical Center is beneficial in diagnosing cases of cellulitis and pseudocellulitis conditions. Prior studies have indicated that misdiagnosis may occur in up to 28% of patients in the ED with these conditions. Additionally, dermatological consults have been shown to change diagnosis or management of these conditions in more than 60% of the patients examined. Without the use of teledermatology, however, a dermatological consult would be prohibitively expensive and take time to obtain. The investigator proposes that by utilizing teledermatology in emergency rooms, the investigator can make faster, yet just as accurate, dermatological diagnoses in patients presenting with cellulitis-like symptoms. Subsequently, by reducing the number of misdiagnoses, unnecessary use of antibiotics and hospitalizations will also decrease, lowering health care costs and simultaneously providing patients with faster treatment of the actual dermatologic condition.

Eligibility criteria: Inclusion Criteria:

* Over 18
* Present to the ED with cellulitis-like symptoms, including but not limited to the following: tenderness, redness, swelling, expansive lesion

Exclusion Criteria:

* pregnant
* prisoner

Primary outcomes:
measure: Admission to the hospital
timeFrame: 30 days
Secondary outcomes:
measure: Length of stay in the hospital
timeFrame: 30 days post admission
measure: 30 day readmission rate
timeFrame: 30 days post admission
measure: Antibiotic use
timeFrame: 30 days post admission
Other outcomes:
Locations:
city: Columbus
country: United States
facility: The Ohio State University Wexner Medical Center
state: Ohio
Study officials:
affiliation: OSU Dermatology
name: Benjamin H Kaffenberger, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00172458: Clinical Results and Restenosis Analysis of Symptomatic Ostial Vertebral Artery Stenosis Treated With Tubular Coronary Stents
Official title: Clinical Results and Restenosis Analysis of Symptomatic Ostial Vertebral Artery Stenosis Treated With Tubular Coronary Stents
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Vertebral Artery Stenosis
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2005-09-15
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: DEFINED_POPULATION
Time perspective: RETROSPECTIVE

Brief summary: Vertebral artery stenosis (VAS) decreases posterior brain perfusion, causing vertebrobasilar insufficiency (VBI). It is also an important embolic source to the posterior brain. The most frequently involved location is the proximal part of the vessel, including the ostium. Various surgical procedures have been described for the treatment of proximal VAS with symptoms refractory to medical therapy, but all are technically difficult with high operative mortality and morbidity.

Endovascular intervention has been described as an alternative to surgery. Balloon angioplasty is limited by elastic recoil and dissection. The restenosis rates reported in the literature varied, as high as 75 %. Stenting offers salvage following unsuccessful balloon angioplasty, and primary stenting have been shown to be safe and effective with lower restenosis rate. Coronary equipments are ideal for ostial VAS, considering the size of the artery and location of the lesion. Recently, Albuquerque et al. reports a relative high restenosis rate in a longer follow-up duration. Restenosis seems to become an important issue regarding the patients' quality of life. However, there is no clinical parameter to predict restenosis of VAS. The purpose of this study is to evaluate the clinical results of our series of symptomatic ostial VAS treated exclusively with tubular balloon expandable coronary stents. We sought to identify predictors of restenosis.

This is a clinical observation study. Only chart review and angiographic review will be performed.


Eligibility criteria: Inclusion Criteria:

Patients with symptomatic vertebral artery stenosis treated by stenting

Exclusion Criteria:

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Hesien-Li Kao, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03906058: Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy
Official title: Open-Label, Phase Ⅱ Study of Anlotinib Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of no Less Than Second-line Chemotherapy or Targeted Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Nasopharyngeal Carcinoma
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2019-04-08
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this single arm, phase Ⅱ clinical trial is to evaluate the efficacy and safety of Anlotinib Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma after failure of no less than second-line chemotherapy or targeted therapy


Eligibility criteria: Inclusion Criteria:

* biopsy proved nasopharyngeal carcinoma;
* stage IVB according to American Joint Committee on Cancer(AJCC) edition VIII, or recurrent disease after chemotherapy and/or radiotherapy;
* 18 years or older; without other malignancy;
* proper functioning of the major organs.

Exclusion Criteria:

* allergic to anlotinib;
* female within gestation period or lactation;
* patients received drug of other clinical trial within 4 weeks.

Primary outcomes:
measure: disease control rate
timeFrame: 30 months
Secondary outcomes:
measure: overall response rate
timeFrame: 30 months
measure: progression-free survival
timeFrame: 30 months
measure: overall survival
timeFrame: 30 months
measure: duration of response
timeFrame: 30 months
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
state: Guangdong
Study officials:
References:
Clinical trial NCT02951858: Substance Use Screening Among Drug User
Official title: Screening and Brief Interventions for Substance Use in Primary Medical Institution
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Substance Use
Keywords: Alcohol,Smoking,and Substance Use Involvement Screening Test
Brief Intervention
Substance Use
Primary Medical and Health Care Institution
Lead sponsor: Shanghai Mental Health Center
Sponsor class: OTHER
First posted: 2016-11-01
Enrollment: 218
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this research is to improve the ability of primary medical staffs in screening and intervention for alcohol, benzodiazepines, and other illicit drug use.

Detailed description: In order to reduce the social and personal harm caused by drugs, it is urgent to strengthen the ability of the primary health institutions in screening and intervention the addictive substances use. Firstly, the investigators will invite 10 primary medical staffs and 10 experts in addition to revise the manual of Alcohol, Smoking, and Substance Use Involvement Screening Test (ASSIST) and Brief Intervention (BI). Then, the investigators will recruit 100 medical staffs to participate the training of ASSIST and BI. Secondly, the researcher will investigate the effects of BI technology in reducing the use of addictive substances, improve the addiction related knowledge of patients through randomized controlled study. Finally, the investigators will collect the research information, revise the manual, and promote the training.

Eligibility criteria: Inclusion Criteria:

1. aged 18-60 years;
2. the patient to the community medical institutions;
3. ASSIST score is in 12-27, in a moderate risk;
4. voluntary to participate;
5. to agree to complete baseline interviews and follow-up studies.

Exclusion Criteria:

1. unable to complete the questionnaire;
2. serious physical illness, action inconvenience.

Primary outcomes:
measure: Risk Behaviors measured by ASSIST questionnaire
timeFrame: 1 month
measure: Knowledge related to Substance Use measured by Knowledge related to Addiction questionnaire
timeFrame: 1 month
measure: Motivation measured by Pre-treatment Readiness Scale
timeFrame: 1 month
Secondary outcomes:
measure: Depression measured by Self-Rating Depression Scale
timeFrame: 1 month
measure: Anxiety measured by Self-Rating Anxiety Scale
timeFrame: 1 month
measure: Self-esteem measured by Self-esteem questionnaire
timeFrame: 1 month
Other outcomes:
Locations:
Study officials:
affiliation: Shanghai Mental Health Center
name: Jiang Du, M.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00227058: Effects of Orotic Acid Derivatives With or Without Glutathione on Allergic Rhinitis
Official title: Effects of Orotic Acid Derivatives With or Without Glutathione on Allergic
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Seasonal Allergic Rhinitis
Keywords: allergic rhinitis
Lead sponsor: University of Mississippi Medical Center
Sponsor class: OTHER
Collaborators: name: Kyowa Hakko Kogyo Co., Ltd.
First posted: 2005-09-27
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to learn if two nutritional supplements, Orotic Acid and Glutathione will have any effect on the immune system response and if there will be any effect on the symptoms of seasonal allergies. It is our thinking that they will have an positive effect.

Detailed description: Current therapy for most immune-based diseases center around the use of anti inflammatory agents, many of which have unpleasant or dangerous side effects. Allergic rhinitis affects over 40 million Americans and its morbidity results from a combination of physical and psychological symptoms. The primary immunopathology has been defined as an imbalance of TH1/TH2 cytokines production resulting in increased allergen-specific IgE production, mast cell activation and eosinophil recruitment/activity. Metallic salts of orotic acid (OR), a natural intermediate in pyrimidine nucleic acid synthesis have been utilized to improve the signs and symptoms of a variety of maladies including the common cold, allergies and as preventatives for cancer and heart disease. Recent studies have reported that moderate doses of OR can mitigate or prevent endocrine and subjective psychological stresses in an acute laboratory stress model. All these findings lead us to hypothesize that OR salts administration will alleviate or eliminate the signs and symptoms associated with seasonal AR through a protective effect that involves direct anti-inflammatory immune effects and/or immunomodulation that include leukocyte trafficking, immunoregulatory cytokine balance and/or decrease inflammatory cell activity.

Eligibility criteria: Inclusion Criteria: Participants must have allergic rhinitis and be skin test positive to Bermuda Grass, Johnson grass, oak tree and/or ragweed, be symptomatic -

Exclusion Criteria: Any significant known heath disease: cardiovascular disease, cancer, or any metabolic disorder, smoker

-

Primary outcomes:
measure: Improvement in nasal symptom scores from baseline after intervention
Secondary outcomes:
measure: change in cytokine profile with intervention compared to placebo
Other outcomes:
Locations:
city: Jackson
country: United States
facility: University of Mississippi Medical Center
state: Mississippi
Study officials:
affiliation: University of Mississippi Medical Center
name: Gailen D. Marshall, MD/PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01911858: Askina Calgitrol Paste Burns
Official title: Non-controlled Prospective Cohort Study of the Use of Askina® Calgitrol® Paste on III Degree Burns in Adults
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Third Degree Burns
Lead sponsor: BBraun Medical SAS
Sponsor class: INDUSTRY
First posted: 2013-07-30
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: The purpose of the study is to demonstrate that Askina® Calgitrol® Paste is safe to use on III degree burns by quantifying the concentration of silver in the blood during treatment and thus to show that the amount of silver absorbed will be no greater than those reported in the literature.


Eligibility criteria: Inclusion Criteria:

* Adults (≥\>18 years age). No upper age limit
* III degree thermal burns from 2-30% TBSA as determined by the Rule of Nines
* Patients who underwent initial treatment within 24 hours after the injury at the latest
* Patients who underwent initial treatment directly at the Burn Centre of FNKV or the initial treatment was in accordance with the standard of care of the Centre
* All patients will have been hospitalised
* Patients who are capable of giving signing informed consent and have done so.

Exclusion Criteria:

* Patients with electrical or chemical burns
* Patients with already infected wounds
* Patients taking systemic antibiotics on admission
* Patients pregnant or lactating
* Patients who fall into "vulnerable population" group with respect to informed consent or who are not capable of giving informed consent
* Patients who used or were treated with silver products for other reasons than treatment of the acute burn in the last 3 months
* Patients whose other burn wounds are being treated with silver products.
* Patients receiving renal dialysis
* Known allergy or sensitivity to any of the ingredients in Askina® Calgitrol® Paste.
* Simultaneous participation in another interventional clinical trial

Primary outcomes:
measure: The quantification of the amount of silver found in plasma during the treatment
timeFrame: Change from Baseline in Blood at 3 days
measure: The quantification of the amount of silver found in plasma during the treatment
timeFrame: Change from Baseline in Blood immediately after the removal of the last investigational dressing (the day before necrotomy, an expected average between 3-10 days after inclusion)
Secondary outcomes:
measure: Wound bed and periwound skin conditions
timeFrame: At each dressing change (an expected average of one day)
measure: Clinical signs of infection
timeFrame: At each dressing change (an expected average of one day)
measure: Patient comfort
timeFrame: At each dressing change (an expected average of one day)
measure: Number of dressing changes
timeFrame: At each dressing change (an expected average of one day)
measure: Adverse Events or Adverse device related event
timeFrame: At each dressing change
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02004158: Positive Psychology to Improve Healthy Behaviors After an Acute Coronary Syndrome
Official title: Study of a Positive Psychology Program to Improve Healthy Behaviors After an Acute Coronary Syndrome: Proof of Concept Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Coronary Syndrome
Keywords: Acute coronary syndrome
Health behavior
Mental health
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: National Heart, Lung, and Blood Institute (NHLBI)
First posted: 2013-12-06
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In this proof-of-concept study, the investigators will assess the ease and usefulness of a positive psychology program in patients with acute coronary syndrome and less-than-optimal adherence to health behaviors. The investigators believe that positive psychology (a field that studies boosting positive emotions rather than simply reducing negative emotions) will help this cardiac population to be more healthy. The investigators want to determine whether this positive psychology program has the potential to be an adjunctive treatment for cardiac populations.


Eligibility criteria: Inclusion Criteria:

* Adult patients admitted to one of three cardiac inpatient units at Massachusetts General Hospital.
* Primary diagnosis of acute coronary syndrome (myocardial infarction or unstable angina).
* Less-than-optimal adherence to health behaviors. This will be defined as a mean score of less than 15 on the Medical Outcomes Study Specific Adherence Scale (scores range from 3-18, with higher scores indicating better adherence).

Exclusion Criteria:

* Cognitive deficits, assessed via a 6-item cognitive screen used to assess appropriate participation of medically-ill patients in research studies.
* Patients not prescribed aspirin at discharge.
* Inability to communicate in English.
* Inability to participate in physical activity.

Primary outcomes:
measure: Rate of Exercise Completion
timeFrame: 8 weeks
measure: Ease of Exercises
timeFrame: 8 weeks
measure: Self-reported Psychological Impact of Exercises
timeFrame: 8 weeks
Secondary outcomes:
measure: Objective Psychological Impact of Exercises
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Jeff Huffman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01837758: Monitoring Platelet Function During Continuous Hemodialysis
Official title: Changes in Platelet Function During Continuous Veno-venous Hemodialysis Using the Multiplate Device
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Platelet Function
Keywords: Platelet function
hemofiltration
Multiplate
Lead sponsor: Goethe University
Sponsor class: OTHER
First posted: 2013-04-23
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients in an intensive care unit with the need for a renal replacement therapy-

Brief summary: Aim of the study is a description of changes in platelet function during continuous veno-venous hemodialysis or hemofiltration in patients on an intensive care unit using the Multiplate system.


Eligibility criteria: Inclusion Criteria:

* Need for a continuous renal replacement therapy
* Platelet Count \>100.000/nl

Exclusion Criteria:

* Pregnancy
* Age \<18 years
* Renal replacement therapy within the 7 days prior to enrollment

Primary outcomes:
measure: ASPItest
timeFrame: Baseline, 6, 12, 24 and 48 hours
Secondary outcomes:
measure: ADPtest
timeFrame: Baseline, 6, 12, 24 and 48 hours
measure: TRAPtest
timeFrame: Baseline, 6, 12, 24, 48 hours
measure: CT-INTEM
timeFrame: Baseline, 6, 12, 24 and 48 hours
measure: MCF-INTEM
timeFrame: Baseline, 6, 12, 24 and 48hours
Other outcomes:
measure: Age
timeFrame: Baseline
measure: Height
timeFrame: Baseline
measure: Weight
timeFrame: Baseline
measure: Gender
timeFrame: Baseline
measure: ASA-Classification
timeFrame: Baseline
measure: Antiaggregatory Premedication
timeFrame: Baseline
measure: Dialysis filter
timeFrame: Basline
measure: Anticoagulation for hemofiltration
timeFrame: Baseline
Locations:
city: Frankfurt
country: Germany
facility: Johann Wolfgang Goethe-University
state: Hessen
Study officials:
References:
citation: Daugirdas JT, Bernardo AA. Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopenia. Kidney Int. 2012 Jul;82(2):147-57. doi: 10.1038/ki.2012.130. Epub 2012 May 16.